Rite Aid

Rite Aid Corp. engages in the ownership and management of retail drug stores. It operates through following segments: Retail Pharmacy and Pharmacy Services. The Retail Pharmacy segment includes branded and generic prescription drugs, health and beauty aids, personal care products, and walk-in retail clinics. The Pharmacy Services segment offers transparent and traditional pharmacy benefit management for insurance companies, employers, health plans, and government employee groups. The company was founded by Alex Grass on September 12, 1962 and is headquartered in Philadelphia, PA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Rite Aid Corp. engages in the ownership and management of retail drug stores. It operates through the Retail Pharmacy and Pharmacy Services segments. The Retail Pharmacy segment includes branded and generic prescription drugs, health and beauty aids, personal care products, and walk-in retail clinics. The Pharmacy Services segment offers transparent and traditional pharmacy benefit management for insurance companies, employers, health plans, and government employee groups. The company was founded by Alex Grass on September 12, 1962 and is headquartered in Philadelphia, PA.

Rite Aid is a health products and services company with 2,400 locations across 17 states.

The company's omnichannel business includes digital, retail, and delivery touchpoints. Rite Aid is a top 20 seller of speciality medications, per its investor website.

In addition to its retail business, Rite Aid owns a pharmacy benefits subdivision (Elixir) and a personalized health services and coaching arm, Health Dialog, which has served 10MM members as of May 2022.

The company has reported $1.85 billion of liquidity with no debt maturities until 2025. According to its investor website, Rite Aid expects to be free cash flow (FCF) positive in FY23.

In Q2 2022, Rite Aid shared a three-part growth strategy aimed at deepening market share, expanding into new markets, and creating new offerings.

To grow the current business, Rite Aid is aiming to increase its e-commerce and digital sales, refresh its loyalty program, and grow its specialty pharmacy offering, which focuses on serving customers with complex health conditions.

New market expansion plans include increasing Rite Aid's footprint of "small format" pharmacies in underserved communities and implementing "store within a store" partnerships.

Rite Aid also aims to grow via new offerings, such as expanded health plan and health system clinical services, a pharmacy benefit manager (PBM) as a service offering, and new strategic partnerships.

Rite Aid Investor Relations

*This is not investment advice.

LOS ANGELES, CA / ACCESSWIRE / May 5, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Rite Aid Corporation ("Rite Aid" or "the Company") (NYSE:RAD) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between April 26, 2018 and March 13, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before May 19, 2023.

FINAL DEADLINE THIS MONTH: The Schall Law Firm Encourages Investors in Rite Aid Corporation with Losses to Contact the Firm

Shares of Bio-Rad Laboratories Inc. BIO tumbled 17.5% toward their worst day in 36 years, after the maker of products for the life science research and clinical diagnostics markets reported first-quarter results that missed expectations, amid a drop in COVID-related sales, and cut its full-year outlook. The stock, which paced the S&P 500's SPX decliners, was headed for the biggest one-day decline since it plunged 23.5% on Oct. 20, 1987.

Bio-Rad's stock leads the S&P 500 decliners, as they suffer the biggest selloff in 36 years after disappointing results.

LOS ANGELES, CA / ACCESSWIRE / May 4, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Rite Aid Corporation ("Rite Aid" or "the Company") (NYSE:RAD) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between April 26, 2018 and March 13, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before May 19, 2023.

FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in Rite Aid Corporation with Losses of $100,000 to Contact the Firm

NEW YORK--(BUSINESS WIRE)---- $RAD #RAD--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Rite Aid Corporation (NYSE: RAD) between April 26, 2018 and March 13, 2023, both dates inclusive (the “Class Period”), of the important May 19, 2023 lead plaintiff deadline in the securities class action commenced by the Firm. SO WHAT: If you purchased Rite Aid securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees o.

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Rite Aid Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action Filed by the Firm – RAD

LOS ANGELES, CA / ACCESSWIRE / April 28, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Rite Aid Corporation ("Rite Aid" or "the Company") (NYSE:RAD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between April 26, 2018 and March 13, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before May 19, 2023.

FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in Rite Aid Corporation with Losses to Contact the Firm

NEW YORK , April 26, 2023 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Rite Aid Corporation (NYSE: RAD) between April 26, 2018 and March 13, 2023, both dates inclusive (the "Class Period"), of the important May 19, 2023 lead plaintiff deadline in the securities class action commenced by the Firm. SO WHAT: If you purchased Rite Aid securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Rite Aid Corporation Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action Filed by the Firm - RAD

PHILADELPHIA--(BUSINESS WIRE)--It's no secret seasonal allergies are here. From runny noses and itchy eyes to tissues carried in all pockets and bags, spring has sprung and mother nature has brought the dreaded sneeze with her. To help its suffering shoppers, Rite Aid has spent the last few weeks dusting off last season's sales data* and speaking with real allergy victims to once and for all ‘Ease the Sneeze.' B.T.S. (Behind the Sneeze) with Real Allergy Sufferers With a curiosity for allergy h.

Rite Aid Looks to ‘Ease the Sneeze' This Allergy Season

CVS Health

Walgreens

Zacks Retail Pharmacy and Drugstore industry players like CVS, WBA and RAD are likely to gain on the strength of their digital pharmacies.

3 Retail Pharmacy and Drugstore Stocks to Watch in a Growing Industry

Rite Aid's (RAD) Q4 results gain from improvements in retail pharmacy and Elixir. However, lower revenues from COVID vaccines and testing, and store closures act as headwinds.

Rite Aid (RAD) Q4 Loss Wider Than Expected, Revenues Beat

Rite Aid Corporation (RAD) Q4 2023 Earnings Call Transcript.

Rite Aid Corporation (RAD) Q4 2023 Earnings Call Transcript

Rite Aid Corp (NYSE:RAD) stock is down 9.3% to trade at $2.15 at last glance, after the company's wider-than-expected first-quarter losses of $1.24 per share.

Rite Aid Stock Suffers Post-Earnings Slide

Rite Aid (RAD) came out with a quarterly loss of $1.24 per share versus the Zacks Consensus Estimate of a loss of $0.77. This compares to loss of $1.63 per share a year ago.

Rite Aid (RAD) Reports Q4 Loss, Tops Revenue Estimates

Rite Aid reported a quarterly loss of more than $241 million as the struggling drugstore chain suffers from a loss of revenue from store closures on top of the loss of COVID-19 vaccine and testing sales.

Rite Aid Losses Hit $241 Million As Stores Close And Covid Test And Vaccine Sales Drop

Rite Aid Corp. RAD, -5.95% stock dropped 7% in premarket trades after the drug store chain reported a wider-than-expected loss and issued guidance that fell short of estimates. Rite Aid said it lost $241.3 million, or $4.39 loss per share in its fiscal fourth quarter, compared to a loss of $389.06 million, or $7.18 a share in the year-ago quarter.

Rite Aid stock drops 7% in premarket after reporting wider-than-expected loss

PHILADELPHIA--(BUSINESS WIRE)--Rite Aid Corporation (NYSE: RAD) today reported operating results for its fourteen-week fourth quarter and fifty-three-week fiscal year ended March 4, 2023. “Our fourth quarter results were at the higher end of our guidance and above consensus, driven by encouraging results in retail pharmacy and year over year improvement for the quarter at Elixir,” said Elizabeth “Busy” Burr, interim chief executive officer.

Rite Aid Corporation Reports Fiscal 2023 Fourth Quarter and Full Year Results and Provides Fiscal 2024 Outlook

The cash-strapped drugstore chain is looking for a permanent leader amid declining demand and looming legal challenges.

Rite Aid Seeks Direction as Sales Slow

Higher non-COVID prescriptions, strength in PBM and delivery service expansion are likely to have impacted Rite Aid's (RAD) Q4 performance amid sluggishness in Retail Pharmacy and Pharmacy Services.

Factors Likely to Influence Rite Aid (RAD) in Q4 Earnings

NEW YORK--(BUSINESS WIRE)-- #A--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Rite Aid Corporation (“Rite Aid” or the “Company”) (NYSE: RAD) in the United States Ohio Northern District Court on behalf of all persons and entities who purchased or otherwise acquired Rite Aid securities between April 26, 2018 and March 13, 2023, both dates inclusive (the “Class Period”).

RITE AID ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Rite Aid Corporation and Encourages Investors to Contact the Firm

NEW YORK , April 6, 2023 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Rite Aid Corporation (NYSE: RAD) between April 26, 2018 and March 13, 2023, both dates inclusive (the "Class Period"), of the important May 19, 2023 lead plaintiff deadline in the securities class action commenced by the firm. SO WHAT: If you purchased Rite Aid securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

RAD NOTICE: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Rite Aid Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action Filed by the Firm - RAD

CVS is the only one of the three main pharmacy chains that grew revenue in 2022. Walgreens Boots Alliance has the highest-yielding dividend of the three.

Best Pharmacy Stock to Buy Right Now

LE AD PLAINTIFF DEADLINE IS MAY 19, 2023 NEW YORK , April 1, 2023 /PRNewswire/ --  Wolf Haldenstein Adler Freeman & Herz LLP  ("Wolf Haldenstein") announces that a federal securities class action lawsuit  has been filed in the United States District Court for the Northern District of Ohio on behalf of investors who purchased or acquired the securities of Rite Aid Corporation ("Rite Aid" or the "Company") (NYSE: RAD) between April 26, 2018 and March 13, 2023, inclusive (the "Class Period"). A ll investors who purchased shares and incurred losses are  advised  to contact the firm immediately at classmember@whafh.com or (800) 575-0735 or (212) 545-4774.

RITE AID CORPORATION CLASS ACTION ALERT: WOLF HALDENSTEIN ADLER FREEMAN & HERZ LLP REMINDS INVESTORS THAT A SECURITIES CLASS ACTION LAWSUIT HAS BEEN FILED IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF OHIO AGAINST RITE AID CORPORATION

Complaint alleges That Rite Aid Corporation Made Misleading Statements Regarding Unlawfully Filled Prescriptions ONTARIO, Calif. , March 30, 2023 /PRNewswire/ -- McCune Law Group, McCune Wright Arevalo Vercoski Kusel Weck Brandt APC (MLG) – a national law firm specializing in Securities Litigation, Commercial Litigation, and Class Actions, is investigating Rite Aid Corporation (NYSE: RAD) ("Rite Aid" or the Company") over allegations that Rite Aid made false and/or misleading statements that failed to disclose the unlawful filling hundreds of thousands of prescriptions for controlled substances that lacked a legitimate medical purpose.

National Law Firm Investigating Rite Aid Corporation Over Alleged False/Misleading Statements That Damaged Investors

NEW YORK , March 29, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Rite Aid Corporation (NYSE: RAD) between April 26, 2018 and March 13, 2023, both dates inclusive (the "Class Period"), of the important May 19, 2023 lead plaintiff deadline in the securities class action commenced by the firm. SO WHAT: If you purchased Rite Aid securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Rite Aid Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action Commenced by the Firm - RAD

Did you lose money on investments in Rite Aid? If so, please visit Rite Aid Corporation Shareholder Class Action Lawsuit or contact  Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your rights.

RITE AID CORPORATION (NYSE: RAD) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Rite Aid Corporation (NYSE: RAD)

NEW YORK , March 24, 2023 /PRNewswire/ -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Rite Aid Corporation (NYSE:RAD) ("Rite Aid" or the "Company") and certain of its officers, on behalf of all persons and entities that purchased, or otherwise acquired Rite Aid securities between April 26, 2018 and March 13, 2023, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/rad.

News for Rite Aid Stock (RAD)